Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 11 - 30 save search
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ATRA | $0.6943 5.04% 4.8% 860K
|
Health Technology
|
| O: -1.52%
H: 0.0%
C: 0.0%
treatment ema europe application therapeutics disease positive iot
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: -0.1%
H: 0.3%
C: 0.3%
fibrosis xin therapeutics phase 1 positive topline cudetaxestat
Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer
Published: 2021-11-30 (Crawled : 13:00) - globenewswire.com
ZLAB | $14.97 6.4% 6.01% 460K
|
Health Technology
|
| O: -7.63%
H: 0.0%
C: 0.0%
chinese treatment positive therapy women results cancer topline phase 3 ovarian cancer primec
Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program
Published: 2021-11-30 (Crawled : 13:00) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: 0.0%
disease positive results pre-clinical positive results preclinical
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
Published: 2021-11-30 (Crawled : 12:30) - biospace.com/
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 39.31%
H: 0.0%
C: 0.0%
positive results cancer ovarian cancer trial mirvetuximab topline
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
Published: 2021-11-30 (Crawled : 12:00) - globenewswire.com
FWBI | $2.94 13.08% 11.26% 83K
|
Manufacturing
|
| O: 42.63%
H: 0.0%
C: 0.0%
treatment biopharma test positive gastrointestinal trial covid infections
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
Published: 2021-11-30 (Crawled : 07:00) - globenewswire.com
MOLN | $3.32 -3.54% 3.5K
|
Professional, Scientific, and T...
|
| O: 15.09%
H: 7.56%
C: 3.78%
molecular ensovibep xin sars-cov-2 positive in vitro
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.